Real QULIPTA® patient.

EPISODIC MIGRAINE

Continuous
Control

12 WEEKS

Continuous control with migraine day reductions across 12 weeks1

Graph showing 12-week migraine reduction for episodic migraine. The majority of impact occurred within weeks 1-4. Baseline monthly migraine days was, on average, 7.7. The majority of impact was seen in weeks 1 through 4.

MMD=Monthly Migraine Days.

Latoya
Real QULIPTA patient.

52 weeks

Open-label, long-term safety study for EM

Reductions observed across 52 weeks

 

Exploratory endpoint: Change from baseline in MMD across 52 weeks2,3

Graph showing reduction in monthly migraine days over a 52 week period. Baseline monthly migraine days was, on average, 7.3.

Exploratory endpoint: Percentage of patients who achieved ≥50% MMD reduction at specified intervals3

In Weeks 49-52

Down arrow

84%

of patients achieved ≥50%
MMD reduction3

(n=335)

Graph of patients who achieved 50%-100% MMD reduction: 60% in weeks 1-4 (n=513). 70% in weeks 9-12 (n=466). 75% in weeks 21-24 (n=417). 81% in weeks 33-36 (n=379). 84% in weeks 49-52 (n=335).

Exploratory endpoint: Percentage of patients who achieved 100% MMD reduction at specified intervals3

In Weeks 49-52

Down arrow

48%

of patients achieved 100%
MMD reduction3

(n=335)

Graph of patients who achieved 100% MMD reduction: 21% in weeks 1-4 (n=513). 26% in weeks 9-12 (n=466). 38% in weeks 21-24 (n=417). 40% in weeks 33-36 (n=379). 48% in weeks 49-52 (n=335).

LIMITATIONS: These are observations from the 52-week, open-label safety study for which efficacy measures were not an endpoint. 31/543 (5.7%) discontinued due to adverse events.3 This open-label safety study was not blinded, not controlled, and included inherent self-selection bias for remaining in the trial. Results should be interpreted with these factors in mind.

 

EM=episodic migraine; mITT=modified intention-to-treat; MMD=Monthly Migraine Days.